Christophe Dhalluin
Roche (Switzerland) · 39 works · 3,630 citations · h-index 16
Top works
- Structure and ligand of a histone acetyltransferase bromodomain
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
- Use of a water flip-back pulse in the homonuclear NOESY experiment
- Structural Basis of SNT PTB Domain Interactions with Distinct Neurotrophic Receptors
- Solution Structure of ERK2 Binding Domain of MAPK Phosphatase MKP-3
- HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors
- Structural and Biophysical Characterization of the 40 kDa PEG−Interferon-α2aand Its Individual Positional Isomers
- Magic Angle Spinning Nuclear Magnetic Resonance in Solid-Phase Peptide Synthesis
- Study of Compounds Attached to Solid Supports Using High Resolution Magic Angle Spinning NMR
- Monitoring of a three-step solid phase synthesis involving a Heck reaction using magic angle spinning NMR spectroscopy
- Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)
- Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial
- Structural, Kinetic, and Thermodynamic Analysis of the Binding of the 40 kDa PEG−Interferon-α2a and Its Individual Positional Isomers to the Extracellular Domain of the Receptor IFNAR2
- An Improved Homonuclear TOCSY Experiment with Minimal Water Saturation
- NMR evidence of the stabilisation by the carcinogen N-2-acetylaminofluorene of a frameshift mutagenesis intermediate
- Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
- Letter to the Editor: 1H, 15N and 13C resonance assignments for the bromodomain of the histone acetyltransferase P/CAF
- Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study
- A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A
- Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study